Platelet-Derived Growth Factor (PDGF)-BB, a potent mitogen for mesenchymal cells, also downregulates the expression of multiple smooth muscle (SM) specific markers. However, there is conflicting evidence whether PDGF-BB represses SM marker expression at a transcriptional or posttranscriptional level, and little is known regarding the mechanisms responsible for these effects. Results of the present studies provide clear evidence that PDGF-BB treatment strongly repressed SM α-actin, SM MHC and SM22α promoters in SMCs. Of major significance for resolving previous controversies in the field, we found that PDGF-BB-induced repression of SMC marker gene promoters occurred in sub-confluent but not post-confluent cultures. Of interest, treatment of post-confluent SMCs with a tyrosine phosphatase inhibitor restored PDGF-BB-induced repression whereas treatment of sub-confluent SMCs with a tyrosine kinase blocker abolished PDGF-BB-induced repression, suggesting that a tyrosine phosphorylation event mediates cell-density dependent effects. Based on previous observations that Ets-1 transcription factor is up-regulated within phenotypically modulated neointimal SMCs, we tested if Ets-1 would repress SM marker expression. Consistent with this hypothesis, results of co-transfection experiments indicated that Ets-1 over-expression reduced the transcriptional activity of SM marker promoter constructs in SMCs whereas it increased activity of SM α-actin promoter in endothelial cells.
Introduction
Smooth muscle cells (SMC) are highly specialized cells expressing a unique repertoire of contractile proteins, ion channels and signaling molecules necessary for their contractile function (38).
The differentiation state of SMCs is controlled by a complex combination of local environmental cues such as cell-cell and cell-matrix interactions, neuronal influences and hemodynamic and mechanical forces (38), but also intrinsic factors such as clonal origins (6) . In contrast to cardiac and skeletal muscle cells that are terminally differentiated, SMC can undergo major changes in phenotype depending on physiological or pathological conditions. For example, in tissue culture or in vascular neointimal lesions, SMC display diminished expression of a number of proteins that are characteristic of fully differentiated SMCs including SM α-actin, SM MHC and SM22α (20; 42) . The precise role of phenotypic modulation of SMCs in the etiology of atherosclerosis is unclear, although it is well established that dedifferentiated SMCs exhibit a number of properties including enhanced migration, proliferation, increased production of metalloproteinases, and extracellular matrix synthesis that are likely to play a key role in progression of vascular lesions (46). Nevertheless, the mechanisms and factors that control the process of phenotypic modulation of SMC are very poorly understood.
One factor that has been shown to be highly efficacious in suppressing expression of smooth muscle markers is PDGF-BB. Members of the platelet-derived growth factor (PDGF) family have been implicated in many different patho-physiological conditions including vascular development, wound healing, neoplasia, and atherosclerosis (14) . These molecules have major mitogenic and chemoattractant properties for SMCs and other mesenchymal cells such as fibroblasts and mesangial cells (14) . Moreover, previous studies in our laboratory have indicated that PDGF-BB causes marked decreases in expression of multiple SM differentiation markers including SM α-actin, SM myosin heavy chain (SM MHC) and α-tropomyosin in cultured SMCs (4; 8; 15) . Decreased expression of these markers was not a direct function of the mitogenic effects of PDGF-BB, since the mitogenic response to 10% serum did not elicit a comparable response. In addition, chronic treatment of cultured SMC with PDGF-BB resulted in nearly complete suppression of expression of smooth muscle differentiation markers in the absence of a sustained mitogenic response (4) . These changes were completely reversible in that withdrawal of PDGF-BB resulted in re-expression of SM α-actin and SM MHC (4) . Consistent with these findings, Hayashi et al subsequently showed that PDGF-BB treatment down-regulated expression of h-caldesmon and calponin in cultured gizzard SMC (13) .
There is evidence, albeit controversial, indicating that PDGF-BB-induced repression of SMC marker genes is mediated through both transcriptional and post-transcriptional effects. For example, results of previous studies in our laboratory showed that PDGF-BB-induced decreases in expression of SM α-actin and SM MHC mRNAs were extremely rapid relative to the normal half-life of these transcripts (8) . In contrast, PDGF-BB increased expression of non-muscle β-actin transcripts (7) . These results therefore suggested that at least part of the effect of PDGF-BB was post-transcriptional through selective mRNA destabilization. In contrast, Van Putten et al and Somasundaram et al presented evidence based on transient transfection studies that PDGF-BB treatment of SMCs repressed the activity of the SM α-actin promoter (58) and the SM MHC promoter (54) . However, these studies did not identify either specific cis-regulatory elements or trans-acting factors that mediated this effect. Moreover, a limitation of these studies was that they involved the analysis of a single SMC promoter and employed truncated SMC promoter constructs known to be insufficient for conferring appropriate expression of these genes in SMCs in vivo (29; 31).
Our laboratory and others previously defined the minimal regions of the SM α-actin, SM MHC and SM22α genes in transgenic reporter systems that recapitulated the expression of the endogenous genes throughout development and in adult mice (1; 17; 29; 31). Moreover, our studies of the effect of endothelial denudation on the expression of reporter genes in these transgenic mice indicated that expression of these promoter constructs was repressed in response to vascular injury in vivo (42). Thus, results indicate that the SM promoter constructs that we previously described contain all the cis-regulatory elements necessary to transduce signals generated from physiological and pathological stimuli, such as vascular injury, into modulation of SM markers expression.
Given that it is not clear if PDGF-BB decreases expression of SM markers at the transcriptional or post-transcriptional level, the initial goal of the present studies was to test the effect of PDGF-BB on the activity of the SM marker promoter constructs that have been characterized in transgenic mice. We found that the expression of the SM α-actin, SM MHC and SM22α promoter-reporter constructs was markedly repressed after PDGF-BB stimulation in sub-confluent SMCs and not in post-confluent SMC cultures. We subsequently initiated a series of experiments to determine the potential mechanisms whereby these promoters were inhibited by PDGF-BB, and specifically tested the possible role of Ets-1, a transcription factor previously shown to be up-regulated after PDGF-BB stimulation and during vascular injury (11; 16) . Of interest, we provide novel evidence showing that Ets-1 is a very potent and selective inhibitor of SMC-specific gene expression. Reporter assays. All transient transfection experiments were performed in triplicate using Superfect transfection reagent (Qiagen Operon) as indicated by manufacturer. Cells were incubated for 3 hours in the presence of 2µg DNA/well and 10 µl Superfect/well for 6-well or 10µg DNA/dish and 60µl
Superfect for 100-mm dishes. Cells were cultured afterwards as described for each experiment. Cells were harvested using Passive Lysis Buffer (Promega). Cell extracts were assayed for luciferase expression using enhanced luciferase assay kit (Beckton Dickinson, Franklin Lakes, NJ) and for protein amount using Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL) as indicated by the manufacturers.
Relative promoter activities are expressed as luminescence relative units normalized for protein content in cell extracts. Results displayed average data ± standard deviation obtained from a triplicate experiment.
Results in every figure are representative of at least three different experiments. Comparisons between treatment groups were analyzed by one-way ANOVA or by Student's t-test as specified in the figure legends. Differences between treatment groups for which p≤0.05 were considered statistically significant (23) .
Stable transfected clones preparation and analysis. SMCs were transfected using supercoiled Ets-1-expressing plasmid DNA. Stably transfected cells were selected using geneticin (Invitrogen) 200 µg/mL. Seven cell lines (named A1 to A4 and B1 to B7) were recovered after cloning the resistant cells.
For characterization and analysis, cells were cultured in absence of geneticin to avoid interference with experiments. Western blot analysis was performed the same way as already described (18) using rabbit anti-human Ets-1 N-276 polyclonal antibody (Santa Cruz Biotech., Santa Cruz, CA). For Northern blot analysis, total cytoplasmic RNA were extracted, separated and transferred on nylon membrane as already described (12) . SM α-and NM β-actin mRNA were detected with a 512-bp EcoRI fragment that encoded amino acids 202 to 374 of human skeletal α-actin cDNA. Ets-1 mRNA were detected with a 324-bp (17; 27) . We also tested a -2,500/+186 mouse ACLP promoter construct that has previously been shown to drive high level expression in SMC and in other non-SMC tissues in transgenic mice (25). Of interest, the ACLP gene is activated in neointimal SMC during vascular injury suggesting that it may be induced by PDGF-BB. As a positive control, cells were transfected with a luciferase construct under the control of the c-fos promoter (-356/+109) (10), which is known to be activated by PDGF-BB (49). Results of these analyses indicated that PDGF-BB 30 ng/ml repressed expression of SM α-actin, SM MHC and SM22α promoter constructs by 60%, 57% and 45% respectively ( Fig. 1) . In contrast, PDGF-BB increased c-fos promoter activity under the same experimental conditions, whereas PDGF-BB had no effect on the ACLP promoter. PDGF-BB treatment also had no effect on expression from a SV40 promoter-luciferase construct and a promoterless-luciferase construct (data not shown). Taken together, these results provide clear evidence that PDGF-BB down-regulates transcription of multiple SMC marker gene promoter-enhancer constructs, and that effects were selective in that PDGF-BB had no effect on transcription of several non-SMC genes. Owens unpublished data), these experiments necessarily required development of experimental protocols that allowed independent control of cell density yet also resulted in adequate efficiency of transfection.
PDGF-BB-Induced
This was accomplished by sub-culturing cells at high or low cell density after transient transfection ( Fig.   2A ) (see Material and Methods section). Of interest, results clearly showed that PDGF-BB treatment had no effect on SM α-actin promoter activity when cells were at high density (Fig. 2B ). In contrast, a decrease in promoter activity was observed after PDGF-BB treatment when cells were plated at low density. Similar results were observed using the SM-MHC promoter-luciferase construct (data not shown). These results provide novel evidence indicating that the repressive effect of PDGF-BB on transcription of SM α-actin gene is cell density-dependent.
An increase in protein-tyrosine phosphatase expression has previously been shown to be responsible for blocking PDGF-BB-induced autophosphorylation of the PDGF-β receptor at high cell density (40; 55). Thus, to determine whether density-dependent increases in tyrosine phosphatases might contribute to loss of PDGF-BB-induced repression of SM α-actin in confluent SMC, cells were treated with orthovanadate, a potent inhibitor of protein phosphatases ± PDGF-BB at low and high cell densities.
Results showed that the activity of the SM α-actin promoter was significantly repressed following treatment of high density cultures with PDGF plus orthovanadate ( Fig. 2B ), whereas at low density orthovanadate did not significantly affect PDGF-BB induced repression of the SM α-actin promoter. The effect of orthovanadate at high density was dose-dependent with maximal effects at 75µM (data not shown). Given that treatment with orthovanadate may induce non-specific effects, we can not conclude that induction of tyrosine phosphatase expression is responsible for the inhibitory effect of high density on PDGF-BB response. Nevertheless, the observation that orthovanadate can rescue the response to PDGF-BB at high cell density whereas it did not significantly affect the PDGF-BB response at low cell density reinforces the observation that changes occur at high density that prevent PDGF-BB-induced repression of SM α-actin gene expression.
PDGF-β β β β Receptor Activation is required for PDGF-BB-Induced Repression of SM α α α α-Actin
Promoter. PDGF-BB has been shown to bind to both PDGF-α and -β receptors (14) . To determine if the repressive effect of PDGF-BB was dependent on PDGF-β receptor phosphorylation, SMC cultures were pretreated with the tyrphostin AG1295, a tyrosine kinase inhibitor that has been shown to be highly selective for the PDGF-β receptor (21) . AG1295 has previously been shown to block PDGF-BB-induced autophosphorylation of the PDGF-β receptor (2; 21; 48). Different concentrations of AG1295 were used from 0.5 µM to 10 µM (AG1295 IC50 for PDGF-BB-induced DNA synthesis =2.5µM, (21)). At concentrations ranging from 2.5 to 10µM, AG1295 blocked PDGF-BB-induced repression of SM α-actin promoter activity indicating that PDGF-BB induced repression of SM α-actin promoter activity in subconfluent cultures was PDGF-β receptor dependent (Fig. 3) . In contrast, AG1478, a tyrosine kinase inhibitor showing selectivity for the EGF receptor, had no effect on either the basal promoter activity or the response to PDGF-BB (data not shown). Interestingly, at concentrations ranging from 5 to 10 µM, SM α-actin promoter activity was increased after PDGF-BB treatment. This observation suggests: 1) that in the absence of PDGF-β receptor tyrosine kinase activity PDGF-BB may activate a subset of signaling pathways that lead to activation of SM promoters; 2) that there is residual AG1295-insensitive PDGF-β receptor tyrosine kinase activity that can result in activation of SM promoters; and/or 3) that activation of non-PDGB β-receptor pathways (e.g. PDGF α-receptors) may activate (rather than repress) SMC gene expression (see Discussion). Taken together, these observations indicate that PDGF-BB-mediated repression of SM α-actin is dependent on PDGF-β receptor activation but that PDGF-BB may induce differential effects on SMC gene expression through alternative signaling pathways. (Fig. 4) . Results demonstrated that Ets-1 mRNA and protein levels were up-regulated within 2 hours of treatment with PDGF-BB and remained increased at 4 hours. By 8 hours, Ets-1 levels were returned to a basal level. SM α-actin and SM MHC mRNA levels started decreasing by 12 hours of treatment, reached a minimum by 24 hours and began to increase back to pretreatment levels by 36 hours. ACLP mRNA levels were not affected by PDGF-BB treatment. The effects of PDGF-BB on these three genes therefore were correlated with the effects of PDGF-BB observed on the promoter-reporter constructs. As reported previously, PDGF-BB also induced a slight increase in GAPDH mRNA levels (41).
Ets-1 Transcription Factor Over-Expression
To determine if Ets-1 had the potential to modulate smooth muscle promoter activity, we examined the effect of Ets-1 over-expression in cultured SMCs. Rat aortic SMCs were transfected with SM reporter constructs and a plasmid construct expressing Ets-1. Results showed that the -2,555/+2,813 SM α-actin and -4,200/+11,600 SM MHC promoters were strongly repressed by Ets-1 over-expression in a dose-dependent manner (Fig. 5 ). SM22α promoter activity was also significantly repressed. In contrast, the activity of the ACLP promoter was not influenced by Ets-1 over-expression, whereas the c-fos promoter was activated. These results showed that Ets-1 induced the same pattern of changes in SMC gene expression as did PDGF-BB.
To delineate the minimal region of the SM α-actin promoter that could mediate PDGF-BB-and
Ets-1-induced repression, a series of deletion mutants of the SM α-actin promoter were constructed and tested in reporter assays. The -153/+20 sequence contains the CArG-A and CArG-B and the TCE cisregulatory elements and was shown in our lab to be the shortest sequence that retains transcriptional activity in cultured SMCs. The -153/+2,813 sequence contains the complete first exon and first intron of the SM α-actin gene and was used to test the role of the first intron. Whereas basal activities of the three different constructs were different, all three constructs were repressed equivalently by PDGF-BB and Ets-1 (Fig. 6 ). These results indicate that the -153/+20 region is sufficient to confer both PDGF-BB-and Ets-1-induced repression. To test if Ets-1 over-expression exhibited cell type selectivity, a series of SM α-actin reporter/Ets-1 cotransfection studies were conducted in endothelial cells. Consistent with previous observations, the -153/+20 SM α-actin promoter construct displayed substantial promoter activity (15.1-fold ±3.2 over promoterless) whereas the -2,555/+2,813 SM α-actin construct had a very low activity in endothelial cells (2.4-fold ±0.2 over promoterless) (Fig 7) . Of interest, results showed that Ets-1 over-expression induced an increase in the -153/+20 (4.3-fold ±0.3) and the -2,555/+2,813 (3.6-fold ±0.2) SM α-actin constructs, a level which is similar to the increase in luciferase expression from the promoterless construct (5.3-fold ±0.4) (Fig. 7) . These results suggest that Ets-1 over-expression in endothelial cells induced a general increase in transcription in endothelial cells and that Ets-1 induced repression of the SM α-actin promoter is selective for SMC. Of note, ACLP and c-fos promoter constructs were activated upon Ets-1 over-expression to a much higher level (9.2-fold ±0.8 and 32.8-fold ±5.1 respectively) suggesting specific activating effects in the case of these genes. These results are very interesting in that they show that Ets-1 effects were cell selective having completely opposite effects in SMCs as compared to endothelial cells.
Ets-1 Over-Expression
Ets-1 Over-expression Down-Regulated Expression of the Endogenous SM α α α α-Actin Gene.
Whereas the results of reporter analysis showed that Ets-1 repressed the activity of exogenous SM promoters, such promoters DNA constructs are episomal and may not accurately reflect effects of Ets-1 on expression of endogenous genes. For example, effects might be quite different due to effects of chromatin structure and/or complex protein-nucleic acid interactions. Since the transfection efficiency of cultured SMC is too low to attempt to directly test effects of Ets-1 over-expression on endogenous SM marker gene expression, SMCs were stably transfected with Ets-1 expressing construct, and effects on SM α-actin expression were analyzed. Seven independent clones were obtained and initially analyzed for expression of Ets-1 protein by Western blotting. Four clones (B2, A2, B3, A3) expressed high levels of Ets-1, one clone expressed very low levels of Ets-1 (B1), and two clones (A4, A1) expressed no detectable Ets-1 protein (Fig. 8A) . Total RNAs were analyzed by northern blot for Ets-1, non-muscle β-actin and SM α-actin mRNA expression (Fig. 8B) . Consistent with results from transiently transfected SM promoter-reporter constructs, quantitative analysis of the Northern-blot results indicated that SM α-actin mRNA levels were negatively correlated with Ets-1 mRNA expression levels within these various stable lines (Fig. 8C) . Non-muscle β-actin mRNA levels did not significantly change in the different clones suggesting that Ets-1-induced repression was selective for SM α-actin. Interestingly, the B1 clone that expressed very low levels of Ets-1 displayed an intermediary reduction in SM α-actin expression between high Ets-1-and low Ets-1-expressing clones, suggesting that SM α-actin expression is very sensitive to Ets-1 expression. These results suggest that Ets-1 over-expression in SMCs is capable of down-regulating expression of not only SM α-actin promoter-reporter construct in transient transfection assays, but also the endogenous SM α-actin gene.
PDGF-BB-induced Ets-1 up-regulation is not affected by cell density. Based on observations
that PDGF-BB-mediated down-regulation of SM marker promoter was cell density-dependent and that
Ets-1 expression is up-regulated by PDGF-BB, we hypothesized that PDGF-BB may be unable to increase Ets-1 expression when cells are cultured at high cell density. In fact, results indicated that Ets-1 mRNA levels were also up-regulated by PDGF BB at high cell density (Fig. 9 ) whereas SM α-actin mRNA levels were decreased. The latter observation is consistent with our previous observations that 
Discussion
The goals of the present study were to identify molecular mechanisms whereby PDGF-BB induces down-regulation of expression of SM marker genes in cultured SMC, and to identify factors and mechanisms involved in this process. Our results provide clear evidence that PDGF-BB selectively repressed transcription of multiple SM marker genes, and that effects were cell density-dependent and mediated through the PDGF-β receptor. Moreover, we found that PDGF-BB induced the expression of precursors in blood vessels (53) . As such, it is interesting to speculate that the effects we observed in vivo in low-density cultures of SMCs in some way mimic the effects observed after mechanical disruption of cell-cell and cell-matrix contacts achieved during vessel injury and in low SMC populated vessels during vascular development. These results are also consistent with a possible role for Ets-1 and PDGF-BB in injury-induced decreases in transcription, although it needs to be emphasized that as yet, there is no direct evidence that PDGF BB exerts direct effects on SMC differentiation marker gene expression in vivo at either the transcriptional or post-transcriptional level.
Of interest, we also observed a PDGF-BB-induced increase in Ets-1 expression in post-confluent
SMCs despite the fact that we did not observe transcriptional repression of SMC marker genes under these conditions. Based on our results that orthovanadate treatment conferred PDGF-BB-induced transcriptional repression in high density cells (Fig. 2) , it is interesting to speculate that the density dependence of the response could occur through the interaction of Ets-1 with one or more factors whose activity is sensitive to cell density through some tyrosine phosphatase dependent pathway. Consistent with this possibility, although we found that Ets-1 repressed the activity of the -155/+20 region of the SM α-actin promoter, we did not find any sequence in that region that could be a potential Ets-1 binding site.
Ets-1 consensus binding site has been shown to have the sequence 5'-A/GCCGGAA/TGT/C-3' (37).
Given the extensive body of evidence that control of SMC gene expression is dependent on complex combinatorial interactions of many cis elements and trans binding factors (see review (22)), and based on these lines of evidence, we speculate that Ets-1-and PDGF-BB-mediated repression of SM marker promoters may be regulated, at least in part, through complex interactions of multiple trans-regulatory factors and may or may not require Ets-1 binding to DNA. However, much additional work will be needed to directly test this hypothesis, since, at present, little or nothing is known regarding potential interactions of Ets-1 with transcription factors known to be required for SMC gene expression in SMCs.
A provocative observation in the present studies was that selective inhibition of the PDGF-β receptor using a PDGF tyrosine kinase receptor inhibitor completely reversed the effects of PDGF-BB resulting in marked activation of the SM α-actin promoter. This result suggests that PDGF-BB may elicit very different effects on SM marker transcription depending on the receptor/signaling pathway activated.
One possibility is that PDGF-BB-induced activation of SM α-actin promoter is mediated through activation of the PDGF-α receptor. Indeed, cultured SMC express the two known PDGF receptor subunits, α and β. Both α and β sub-units bind the PDGF-B chain, whereas the α sub-unit only binds the PDGF-A chain. However, PDGF-BB-mediated increase in SM α-actin promoter activity is probably not related to the activation of PDGF-α receptor since we found that PDGF-AA had no effect on expression of any of the SMC promoter reporter constructs tested (data not shown). Another possibility is that hours. All treatments were harvested at the same time. Cell extracts were made and proteins were analyzed by western-blot using an anti-Ets-1 antibody. Quantitative analysis of northern blot was done using a phosphorimager. Graph shows quantification results from a representative experiment and indicates ratio of SM α-actin band intensity normalized to NM β-actin band intensity (C). 
